Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of the btl-fr2000 device for the treatment of facial wrinkles

Conditions: Wrinkle

Summary: the study will evaluate safety and effectivity of the btl-fr2000 device for the treatment of facial wrinkles.

subjects will be photographed at the baseline visit. after the treatment phase, subjects will be invited for two follow-up visits - 3 and 6 months after the last therapy. they will be again photographed. three blinded evaluators will be scoring the full face photos according to the fitzpatrick wrinkle severity scale. the improvement of the scores will be evaluated. every subject will serve as its own control. in addition, the occurence of an ae during the whole study, as well as the therapy discomfort during the treatment phase, will be followed.

Eligibility criteria:
inclusion criteria: * age ≥ 22 years * voluntarily signed informed consent form exclusion criteria: * bacterial or viral infection, acute inflammations * impaired immune system * isotretinoin in the past 12 months * skin related autoimmune diseases * radiation therapy and chemotherapy * poor healing and unhealed wounds in the treatment area * history of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin * metal implants * permanent implant in the treated area * pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body * facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment * current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles * history of any kind of cancer * active collagen diseases * cardiovascular diseases (such as cardiac and vascular diseases, peripheral arterial disease, thrombophlebitis, thrombosis, etc.) * pregnancy/nursing or ivf procedure * history of bleeding coagulopathies, use of anticoagulants * any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea * any surgical procedure in the treatment area within the last three months or before complete healing * poorly controlled endocrine disorders, such as diabetes * children under age of 21 * excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks * patients with allergy to anesthetics should not be treated under anesthesia * botox®/collagen/fat injections or other injected bio-material in the treated area within three months prior to treatment * use of non-steroidal anti-inflammatory drugs one week before and after each treatment session * treating over tattoo or permanent makeup
a diagnosis and treatment optimization study of depression based on the neurological mechanism of reward system

Conditions: Diagnosis and Treatment of Depression

Summary: major depressive disorder (mdd) is a high-disabling disease. but its etiology and pathogenesis is not clear, and early recognition, diagnosis and treatment still has many challenges. among numerous clinical manifestations of mdd, anhedonia is an important core symptom of mdd, especially in patients with melancholic features. our previous studies and studies abroad have shown that mdd patients had functional abnormality in reward circuit. the abnormalities of reward-related core areas, such as the prefrontal cortex - nucleus accumbens - ventral tegmental area were closely associated with the development of mdd, and is an important neural basis of anhedonia. this study would take the reward circuit as mainline to carry out the etiology, diagnosis and therapeutic intervention studies of mdd. we would collect mdd patients with melancholic features and other populations with reward dysfunction. the neuroimaging techniques, stress assessment, genetic testing and drug intervention methods would be mainly used in this study. the functional connectivity of reward regions, such as the ventral striatum, nucleus accumben, and ventral medial prefrontal cortex, would be analyzed to identify the dysfunction of reward circuit of mdd, and its implication for early recognition, diagnosis and prediction of treatment efficacy of antidepressants. we would also investigate the effect of genetic and environmental factors on reward function of mdd and its biological basis. finally, through modulating the reward circuit activity using animal experiments, we would verify and investigate reward dysfunction of mdd and its biological mechanisms. the project is expected to provide for new evidence for the establishment of reward mechanism - based objective diagnosis and treatment optimization strategy of mdd.


Eligibility criteria:
inclusion criteria: * first-episode, drug naive melancholic depression; remitted depression; schizophrenia patients; first-degree relatives of depressed patients. exclusion criteria: * major somatic diseases; dsm-iv axis i other mental illness; personality disorder, mental retardation; drug and / or alcohol dependence; serious suicidal tendencies or suicidal behavior; pregnant or lactating women; mri contraindications.
post covid-19 syndrome treatment with variable pulse transcranial magnetic stimulation

Conditions: Post COVID-19 Condition

Summary: the purpose of this study is to test if variable pulse tms (transcranial magnetic stimulation) can result in objective improvements in patients with post covid syndrome (pcs).


Eligibility criteria:
inclusion criteria: * patients who have had a recent episode of covid-19 and who present to the post covid-19 clinic at mayo clinic rochester with at least one of the pcc symptoms of interest - anosmia, tinnitus, fatigue. symptoms consistent with pcc lasting at least 1 month after the positive test date. subjects must have ongoing symptoms for \> 4 weeks following the start of an acute covid infection. this is consistent with the cdc definition for post covid conditions. start date is determined by date of first positive covid test. there is no limitation of maximum time from acute infection start. * at least one of the pcc symptoms of interest: * anosmia: olfactory threshold test scores corresponding to anosmia or hyposmia * tinnitus: \>0 score on tinnitus handicap inventory (not present prior to sars-covid 2 infection) * fatigue: total modified fatigue impact scale (mfis) score of 40 or above exclusion criteria: * implanted electronic devices, including pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators (vns) * active alcohol abuse: \>14 drinks a week or formal diagnosis, illicit drug use or drug abuse * any seizure history within the past 10 years * intracranial implant within 30 cm of magnet (e.g., aneurysm clips, endovascular coil, cerebral shunts, brain stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed * enrolled or plans to enroll in an interventional trial during this study * previous stroke with residual deficits * subjects unable to comprehend or follow verbal commands * subjects unable to comprehend and sign the informed consent * based on pi's or local physician's assessment that subject unable to tolerate the trial procedure due to medical condition * clinical abnormality or clinically unstable medical condition, as indicated by medical history, physical examination, or clinical laboratory testing, that in the investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results * pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required for females of childbearing potential * any condition which in the judgment of the investigator would prevent the subject from completion of the study
relationship between heart failure with preserved ejection fraction and nonalcoholic fatty liver disease.

Conditions: Heart Failure With Preserved Ejection Fraction; Non Alcoholic Fatty Liver

Summary: the aim of our study to determine the demography, relation between patients with heart failure with preserved ejection fraction and those with nonalcoholic fatty liver disease in sohag university hospital.

type of the study cross sectional study to study the relationship between heart failure with preserved ejection fraction and nonalcoholic fatty liver disease.

Eligibility criteria:
inclusion criteria: clinical diagnosis of heart failure with preserved ejection fraction. clinical diagnosis of nonalcoholic fatty liver disease. - exclusion criteria: rheumatic heart disease ,congenital heart disease , ischemic heart disease ,heart failure with reduced ejection fraction , hepatitis b virus , hepatitis c virus . -
effects of (licochalcone a) and paclitaxel on human oral squamous cell carcinoma cell line

Conditions: Squamous Cell Carcinoma

Summary: oral squamous cell carcinoma (oscc) are considered as a one of the most malignant cancers. it has prognosis due to its distant metastasis and obvious destruction which lead to low survival rate. the conventional treatment modalities such as surgery, radiotherapy and chemotherapy are only the suitable strategies until now. investigators cannot ignore the serious side effects of chemotherapy such as gastrointestinal upset, bone marrow suppression which cannot be overcome. for all these complications, there is a great need and demand to discover a new agents and strategies for treating oscc. licorice extract, especially licochalcone a, is one of many natural extracts that have used as a traditional in treatment of inflammation, microbial infections. regarding antitumor effect, licochalcone a reveals interesting results in programmed cell death and apoptosis in cancer cells such as prostate, bladder, colon and gastric cancer.

oral squamous cell carcinoma (oscc) is considered the most common human body malignant tumor. it has poor prognosis regarding its distant lymph node metastasis and local destruction which lead to low survival rate. paclitaxel is a chemotherapeutic drug of the taxols group that is used in the treatment of lung, ovarian and prostate cancer. it is also used to treat breast, head and neck cancer as well as sarcoma and leukemia. recent studies and researches explored that paclitaxel has an important role in mitotic arrest activation and induction, which subsequently lead to cell death. the conventional treatment strategies such as surgery, radiotherapy and chemotherapy come with low levels of expectations regarding prognosis and survival rate. on the other hand, serious side effects of chemotherapy such as renal toxicity, gastrointestinal upset and bone marrow suppression remain hazards which cannot be avoided.thus, there is a great need to discover new agents and strategies for treating oscc or even enhancing the effect of chemotherapy in order to reduce the dose given. licorice extract, licochalcone a, is one of many natural extracts of glycyrrhiza inflata plant. it has been used in treatment of inflammation, infections and cancer.

Eligibility criteria:
inclusion criteria: 1. all head and neck squamous cell carcinoma cell lines 2. licochalcone extracts 3. taxols group of chemotherapy exclusion criteria: 1. animal experimental studies 2. any cancer cell line other than squamous cell carcinoma cell lines. 3. any chemotherapeutics other than taxols group.
revealing microbiome association with (plant-based) diet in freshman

Conditions: Healthy

Summary: aim of the study is to evaluate the impact of a vegan vs. vegetarian dietary pattern compared to an omnivore diet on body weight, saliva and stool microbiome profiles, as well as saliva, urine and plasma metabolome profile changes in freshmen after the first year at university/college.


Eligibility criteria:
inclusion criteria: * freshman * following a vegan / vegetarian / omnivore dietary pattern for at least 3 months * own a smartphone (including internet access and camera) exclusion criteria: * regular use of medication (excluding oral contraceptiva) * use of antibiotics in the last 6 weeks * chronic disease, especially gut diseases * following a vegan / vegetarian / omnivore dietary pattern for less then 3 months * no clear assignment of vegan / vegetarian / omnivore dietary pattern * electrical implants

Keywords: freshman vegan vegetarian omnivore microbiome meal frequency meal timing freshman weight gain metabolome
double-blind study of miglitol in japanese with type2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: to investigate the efficacy and safety of miglitol in japanese patients with type 2 diabetes that is insufficiently controlled diet alone.


Eligibility criteria:
inclusion criteria: * type2 diabetic patient on dietary therapy * criteria for postprandial plasma glucose and hba1c are met exclusion criteria: * type1 diabetes * patients treated with antidiabetic drugs or insulin

Keywords: alpa-glucosidase inhibitor
impact of buccal bone thickness on pathological peri-implant bone loss: a 3-year prospective cohort study

Conditions: Periimplantitis; Oral Surgery

Summary: implant placement may trigger bone trauma, which might result in 3-dimensional bone changes. while the process of peri-implant disease is not well understood, implant position within the bony structure might play a role. however, there is no data available on this regard.


Eligibility criteria:
inclusion criteria: * patients between 18 and 80 years old * patients requiring oral rehabilitation through supported prosthesis * patients with partial edentulism * no antibiotic in the last 2 months * no smoking or smoking \<10 cigarettes a day exclusion criteria: * systemic diseases uncontrolled * implants that because prosthetic characteristics can not be registered probing depth or attachment level appropriately * smoking\> 10 cigarettes a day * pregnant patients * implants that can not be followed in cicom * patients who do not return to regular maintenance therapy every 3-6meses * patients who are not controlled periodontal disease
the a-list wmm insights series

Conditions: Alzheimer Disease; Dementia; Mild Cognitive Impairment

Summary: the main purpose of the study is to develop an understanding over time and through multiple research projects, including surveys, interviews, online focus groups, and other primary research methodologies (a-list research projects) on what matters most to individuals concerned about brain health and those with and/or affected by alzheimer's disease and other dementias, including caregivers.

to do this, usagainstalzheimer's will identify and engage individuals who want to focus on brain health; individuals who are worried about their cognition; individuals who perceive themselves to be at risk for alzheimer's disease (ad); individuals who may be at risk for ad due to self-identified confirmation of underlying disease pathology; individuals who self-identify as having a diagnosis of mild cognitive impairment (mci) or of ad or another dementia; and those who self-identify as current or former caregivers of patients with alzheimer's disease or another dementia to participate in the a-list research projects. such participants will either already be - or will be invited to become - members of the a-list cohort, an online cohort of individuals ready and willing to engage in a-list wmm insights series (a-list members). the a-list wmm insights series will enlist participants to offer insights into a range of issues relevant to alzheimer's, including as examples issues pertinent to clinical trial design, regulatory submissions, other research strategies, payer value determinations, and care and services research. the a-list wmm insights series may seek information that in some instances will be marketing research or other research exempt from irb oversight. however, when an individual a-list research project constitutes human subjects research consistent with governing law, irb approval will be sought and obtained. where questions exist whether an individual a-list research project constitutes human subject research, irb determination will be solicited.

Eligibility criteria:
inclusion criteria: to be eligible to participate in the study, an individual must meet all of the following criteria: 1. age 18 years or older. 2. united states, canada resident. 3. self-report of cognitive difficulties, caregiver status or interest in brain health. 4. have indicated willingness to participate by selecting "i agree" option when joining the a-list. additionally, will have clicked on link - invitation to take a specific survey 5. able to speak, read, and understand english. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. unable to comply with the study requirements.

Keywords: alzheimer dementia cognitive cognition brain health
yoga exercise for improving balance in patients with subacute &ｃhronic stroke

Conditions: Depression; Stroke

Summary: hypothesis: this study investigated the hypothesis that subacute and chronic stroke patients who received a combination of yoga and traditional physiotherapy were getting more improvement in standing balance than traditional physiotherapy. and we also hypothesis yoga can improve post-stroke depression symtom.


Eligibility criteria:
inclusion criteria: 1. the time of stroke onset is more than 91 days. 2. able to stand for more than 1 minutes. 3. between the ages of 30 and 80. exclusion criteria: 1. now receive others palliative therapy. 2. significant psychotic disease. 3. obvious language disorder. 4. medical contraindication(clincans evaluate cannot included).

Keywords: yoga stroke standing balance depression
a follow-up study to evaluate the safety of allo-asc-dfu in allo-asc-bi-101 clinical trial

Conditions: Burn

Summary: this is an open-label follow up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 1 clinical trial(allo-asc-bi-101) for 23 months.

this is an open-label follow up study to evaluate the safety for the subjects with allo-asc-dfu treatment in phase 1 clinical trial (allo-asc-bi-101) for 23 months. allo-asc-dfu is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(vegf) and hepatocyte growth factor (hgf), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.

Eligibility criteria:
inclusion criteria: 1. subjects who are treated with allo-asc-dfu sheet in phase 1 clinical trial of allo-asc-bi-101. 2. a subject who is willing to follow the protocol and provide informed consent on screening, given that the information with respect to the clinical trial is provided. exclusion criteria: 1. subjects who are considered not suitable for the study by the principal investigator. (for example, subjects requiring surgical procedure on target site)

Keywords: deep second-degree burn wound
changes in heart rhythms associated with antipsychotic drug treatment

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder

Summary: this study is being done to look at the electrical activity of the heart. this study will help decide whether taking recordings for a 24-hour period gives more useful information than recording it for a few seconds in a doctor's office. the study will compare 24 hour electrocardiogram (ecg) results of patients taking thioridazine (mellaril) to those of other patients taking different medications that took part in another study.

the objective of the study is to assess the tpe and qtc measures in 24 hr holter echocardiograms in patients treated with atypical antipsychotic drgs (apds). the primary comparisons of interest are olanzapine (no qtc prolongation) to ziprasidone (qtc prolongation) and thioridazine (qtc prolongation) as well as ziprasidone (possibly low tdp risk) to thioridazine (tdp risk). secondary comparisons will be among all apds available. in a previously approved study, conventional 24 hr holter electrocardiograms were recorded from a total of 78 subjects during the course of treatment with psychotropic medications and without medication (in the case of normals and unmedicated patients). these recordings will be analyzed to yield tpe, qtc and heart rate, and other measures. data from additional patients is needed, therefore this study will include only patients currently treated with mellaril (thioridazine), risperdal (risperidone) and seroquel (quetiapine).

Eligibility criteria:
inclusion criteria: * patients must be male or female, age 18-65 * patients must have a definitive diagnosis by dsm-iv criteria of schizophrenia, bipolar or schizoaffective disorder. * patients can be receiving inpatient or outpatient treatment at time of enrollment. * patients must have been treated with (mellaril) thioridazine, (risperdal) risperidone or (seroquel) quetiapine at least three months at time of enrollment. * patients must be able to provide written informed consent exclusion criteria: * patients with a primary diagnosis other than schizophrenia, schizoaffective or bipolar disorder * patients who are currently taking other medications that have been shown to prolong the qtc, including tricyclic antidepressants, fluoroquinolones or antiarrythmics. * patients unable to provide written informed consent.

Keywords: schizophrenia schizoaffective disorder bipolar disorder antipsychotic drug treatment safety arrythmias
effect of ropivacaine during popliteal nerve block in foot and ankle surgery

Conditions: Popliteal Nerve Block; Foot Surgery; Ankle Surgery

Summary: with the increasing rise of outpatient surgery in orthopaedic procedures, the management of immediate postoperative pain has been a major topic investigated, with the use of a peripheral nerve block in combination with general anesthesia being a commonly accepted method. foot and ankle procedures, which offer the choice of several anesthetic techniques, have increasingly been performed with this method predominantly through the combination of general anesthesia with a single-injection popliteal nerve block to reduce the substantial acute postoperative pain that often requires large opioid intake within the post-anesthesia care unit (pacu). however, as a single-injection peripheral nerve block resolves off shortly following surgery, major postoperative pain, termed "rebound pain", can also arise, and has the potential to be even greater than that of patients who do not receive any peripheral nerve block with general anesthesia. the purpose of this study is to evaluate the contribution of ropivacaine concentration (0.5% versus 0.25%) of the initial bolus in continuous popliteal nerve blocks toward the rebound pain phenomena, or the quantifiable difference in pain experienced during the initial time after block resolution, in foot and ankle surgeries.


Eligibility criteria:
inclusion criteria: * all patients undergoing foot and ankle surgeries under the care of dr. steven raikin with continuous popliteal blocks at riverview surgical center will be considered for enrollment. exclusion criteria: * patients who present with a) known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type, * existing use of narcotics, * pregnant women, * individuals under the age of 18 * procedures involving any other forms of anesthesia other than general anesthesia with a continuous popliteal nerve block.